Advertisement

Trastuzumab

  • Giuseppe TridenteEmail author
Chapter

Abstract

Trastuzumab (Herceptin®, Genentech, Roche) is a recombinant humanized IgG1k monoclonal antibody binding with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (HER2).

Keywords

Febrile Neutropenia Combine Therapy Mitochondrial Outer Membrane Permeabilization Cardiotoxic Event Salivary Ductal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_38_MOESM1_ESM.xls (68 kb)
Supplementary material 1 (XLS 69 kb)

References

  1. 1.
    Trastuzumab (Herceptin®) BLA 98-0369 Clinical Review FDA, Sept 1998Google Scholar
  2. 2.
    Trastuzumab (Herceptin®) WC500049816 Scientific Discussion EMEA, Nov 2004Google Scholar
  3. 3.
    Trastuzumab (Herceptin®) WC500049822 Scientific Discussion EMEA, May 2006Google Scholar
  4. 4.
    Trastuzumab (Herceptin®) WC500049823 Scientific Discussion EMEA, Aug 2007Google Scholar
  5. 5.
    Trastuzumab (Herceptin®) BLA 103792/5187/5189 Approval Package FDA, May 2008Google Scholar
  6. 6.
    Trastuzumab (Herceptin®) WC500074921 Assessment Report EMEA, Jan 2010Google Scholar
  7. 7.
    Trastuzumab (Herceptin®) Prescribing Information, Genentech Oct 2010Google Scholar
  8. 8.
    Trastuzumab (Herceptin®) WC500106489 Assessment Report EMEA, Mar 2011Google Scholar
  9. 9.
    Trastuzumab (Herceptin®) WC500074922 EPAR Annex I EMEA, May 2012Google Scholar
  10. 10.
    Nahta R (2012) Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012:428062. doi: 10.5402/2012/428062 PubMedGoogle Scholar
  11. 11.
    Okines AFC, Cunningham D (2012) Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Ther Adv Gastroenterol 5:301–318CrossRefGoogle Scholar
  12. 12.
    Vu T, Claret FX (2012) Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers Oncol. doi: 10.3389/fonc.2012.00062 Google Scholar
  13. 13.
    Hansel TT, Kropshofer H, Singer T et al (2010) The safety and side effects of monoclonal antibodies. Nature Rev (Drug Discov) 9:325–338CrossRefGoogle Scholar
  14. 14.
    Hurvitz SA, Kakkar R (2012) The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol 4:235–245PubMedCrossRefGoogle Scholar
  15. 15.
    Andre F, Dieci MV, Dubsky P et al (2012) Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-11-2701 Google Scholar
  16. 16.
    Kho DK, Namgia-Makker P, Balan V et al (2012) Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res. doi: 10.1158/0008-5472.CAN-12-2149 PubMedGoogle Scholar
  17. 17.
    Romond EH, Jeong J-H, Rastogi P et al (2012) Seven-Year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Cancer 30:3792–3799Google Scholar
  18. 18.
    Aiello EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort analysis. JNCI 104:1293–1305CrossRefGoogle Scholar
  19. 19.
    Pernas S, Gil–Gil M, Oochoa de Olza M et al (2012) Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Breast Cancer Res Treat 134:1161–1168PubMedCrossRefGoogle Scholar
  20. 20.
    Aogi K, Saeki T, Nakamura S et al (2012) A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol doi:  10.1007/s10147-012-0437-1
  21. 21.
    Russo G, Cioffi G, Di Lenarda A et al (2012) Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 7:439–446PubMedCrossRefGoogle Scholar
  22. 22.
    Zagouri F, Sergentanis TN, Chrysicos D et al (2013) Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 137:349–357PubMedCrossRefGoogle Scholar
  23. 23.
    Cardoso F, Canon J-L, Amadori D et al (2012) An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for GER2-positive metastatic breast cancer. Breast 21:716–723PubMedCrossRefGoogle Scholar
  24. 24.
    Valakis A, Nearchou A, Lind P et al (2012) Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res Treat 135:655–662CrossRefGoogle Scholar
  25. 25.
    Kerklaan BM, Diérac V, Le Tourneau C et al (2013) Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemother Pharmacol 71:53–62PubMedCrossRefGoogle Scholar
  26. 26.
    Ismael G, Hegg R, Muehlbauer S et al (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869–878PubMedCrossRefGoogle Scholar
  27. 27.
    LoRusso PM, Weiss D, Guardino E et al (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437–6447PubMedCrossRefGoogle Scholar
  28. 28.
    Roda J, Parhat R, Lamb T et al (2005) Phase I trial of interleukin-12 with trastuzumab and paclitaxel for HER2-overexpressing malignancies. J. Immunother 28:644 (abstract)Google Scholar
  29. 29.
    Safran H, Iannitti D, Ramanathan R et al (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22:706–712PubMedCrossRefGoogle Scholar
  30. 30.
    Harder J, Ihorst G, Heinemann V et al (2012) Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. BJC 106:1033–1038PubMedCrossRefGoogle Scholar
  31. 31.
    Kaidar-Person O, Kuten BS (2012) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29:704–706PubMedCrossRefGoogle Scholar
  32. 32.
    Bronchud MH, Castillo S, Escriva de Romani S et al (2012) HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report. Onkologie 35:769–776CrossRefGoogle Scholar
  33. 33.
    Ahn ER, Wang E, Glück S (2012) Is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity? A discussion of current evidence, recommendations, and ethical issues regarding dual HER2-targeted therapy. Breast Cancer: Basic Clin Res 6:191–207Google Scholar
  34. 34.
    Fralik M, Hilton JF, Bouganim N et al (2012) Dual blockade of HER2—twice as good or twice as toxic? Clin Oncol 24:593–603CrossRefGoogle Scholar
  35. 35.
    Konecny GE (2013) Emerging strategies for the dual inhibition of HER2-positive breast cancer. Curr Opin Obstet Gynecol 25:55–65PubMedCrossRefGoogle Scholar
  36. 36.
    Orphanos G, Kountourakis P (2012) Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther 5:127–137PubMedGoogle Scholar
  37. 37.
    Nielsen DL, Kümler I, Palshof JAE et al (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22:1–12PubMedCrossRefGoogle Scholar
  38. 38.
    Templeton A, Ocaña A, Šeruga B et al (2012) Management of small HER2 overexpressing tumours. Breast Cancer Res Treat 136:289–293PubMedCrossRefGoogle Scholar
  39. 39.
    Filho OM, Saini KS, Azim HA Jr et al (2012) Prevention and management of major side effects of targeted agents in breast cancer. Crit Rev Oncol/Hematol 84:e79–e85CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations